Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)
October 6, 2021 11:16 AM EDTUpdated 04:41 PM
Pharma

A short-sell at­tack sends Ginkgo's share price spin­ning, un­der­scor­ing in­vestors' con­cerns over syn­bio field

Kyle Blankenship

Gink­go Bioworks, a syn­thet­ic bi­ol­o­gy uni­corn that has cap­tured in­vestors’ imag­i­na­tions and trades un­der Genen­tech’s hal­lowed old $DNA tick­er, took a big blow Wednes­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times